Please Wait
Applying Filters...
menu
    • menu
    Evonik

    Virtual Booth

    Contact Supplier

    AbbVie CDMO has been working with global companies to develop, manufacture & scale biopharmaceutical products.

    Virtual Booth

    Contact Supplier

    pharmacompass-1-m-2026-01-12

    Virtual Booth

    An Enquiry

    End-to-end drug development, specializing in high-potency softgels and liquids, providing global partners with a competitive advantage.

    Virtual Booth

    Contact Supplier

    Kewpie is your partner for Sodium Hyaluronate & Hyaluronic Acid// CEP, USDMF, KDMF & JDMF registered.

    Virtual Booth

    Contact Supplier

    pharmacompass-2-m-2025-11-03

    Virtual Booth

    An Enquiry

    Menu

    AMP945

    DEVELOPMENTS

    DIGITAL CONTENT

    PharmaCompass
    Xls

    Filters

    clear-filterReset all filters
    Left Arrow
    Right Arrow

    Digital Content read-more

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Amplia Therapeutics To Present At 2026 ASCO Gi Cancers Symposium
    Amplia Therapeutics To Present At 2026 ASCO Gi Cancers Symposium

    23 Dec 2025

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2025/12/23/3209888/0/en/Amplia-Therapeutics-to-Present-at-2026-ASCO-Gastrointestinal-Cancers-Symposium.html

    GLOBENEWSWIRE
    23 Dec 2025
    Share Share
    Amplia Investor Presentation Reveal Additional Confirmed Response
    Amplia Investor Presentation Reveal Additional Confirmed Response

    12 Dec 2025

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2025/12/12/3204647/0/en/Additional-Confirmed-Response-Reported-as-Part-of-Amplia-Investor-Presentation.html

    GLOBENEWSWIRE
    12 Dec 2025
    Share Share
    Key Narmafotinib Patent Granted In U.S.
    Key Narmafotinib Patent Granted In U.S.

    03 Dec 2025

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2025/12/03/3198906/0/en/Key-Narmafotinib-Patent-Granted-in-the-U-S.html

    GLOBENEWSWIRE
    03 Dec 2025
    Share Share
    Adagene Starts Investigator-Led Ph 2 Trial of Muzastotug
    Adagene Starts Investigator-Led Ph 2 Trial of Muzastotug

    27 Feb 2025

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2025/02/27/3033784/0/en/Adagene-Announces-Investigator-Initiated-Phase-2-Trial-for-Neoadjuvant-Muzastotug-ADG126-in-Colorectal-Cancer.html

    GLOBENEWSWIRE
    27 Feb 2025
    Share Share
    Adagene Updates Muzastotug, Keytruda Data In Colorectal Cancer
    Adagene Updates Muzastotug, Keytruda Data In Colorectal Cancer

    27 Jan 2025

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2025/01/27/3015470/0/en/Adagene-Announces-Updated-Data-from-Phase-1b-2-Study-of-Muzastotug-in-Combination-with-KEYTRUDA-pembrolizumab-in-Colorectal-Cancer-at-ASCO-Gastrointestinal-Cancers-Symposium.html

    GLOBENEWSWIRE
    27 Jan 2025
    Share Share
    Adagene To Present Muzastotug Data With Keytruda At GI Symposium
    Adagene To Present Muzastotug Data With Keytruda At GI Symposium

    21 Jan 2025

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2025/01/21/3013103/0/en/Adagene-to-Announce-Updated-Data-from-Phase-1b-2-Study-of-Muzastotug-in-Combination-with-KEYTRUDA-pembrolizumab-in-Colorectal-Cancer-at-ASCO-Gastrointestinal-Cancers-Symposium.html

    GLOBENEWSWIRE
    21 Jan 2025
    Share Share
    • Privacy policy
    • Terms and conditions
    • Disclaimers
    • LinkedIn
    • Product listings are provided for informational purposes only. We do not supply or sell any products. Any products that may be covered by patent(s) are supplied solely for uses permitted under Section 107A of the Indian Patents Act and not for commercial sale.